Your browser doesn't support javascript.
loading
Lactoferrin as a Component of Pharmaceutical Preparations: An Experimental Focus.
Guzmán-Mejía, Fabiola; Godínez-Victoria, Marycarmen; Molotla-Torres, Daniel Efrain; Drago-Serrano, Maria Elisa.
Afiliación
  • Guzmán-Mejía F; Unidad Xochimilco, Departamento de Sistemas Biológicos, Universidad Autónoma Metropolitana, Ciudad de México CP 04960, Mexico.
  • Godínez-Victoria M; Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Ciudad de México CP 11340, Mexico.
  • Molotla-Torres DE; Unidad Xochimilco, Departamento de Sistemas Biológicos, Universidad Autónoma Metropolitana, Ciudad de México CP 04960, Mexico.
  • Drago-Serrano ME; Unidad Xochimilco, Departamento de Sistemas Biológicos, Universidad Autónoma Metropolitana, Ciudad de México CP 04960, Mexico.
Pharmaceuticals (Basel) ; 16(2)2023 Jan 31.
Article en En | MEDLINE | ID: mdl-37259362
ABSTRACT
Lactoferrin is an 80 kDa monomeric glycoprotein that exhibits multitask activities. Lactoferrin properties are of interest in the pharmaceutical field for the design of products with therapeutic potential, including nanoparticles and liposomes, among many others. In antimicrobial preparations, lactoferrin has been included either as a main bioactive component or as an enhancer of the activity and potency of first-line antibiotics. In some proposals based on nanoparticles, lactoferrin has been included in delivery systems to transport and protect drugs from enzymatic degradation in the intestine, favoring the bioavailability for the treatment of inflammatory bowel disease and colon cancer. Moreover, nanoparticles loaded with lactoferrin have been formulated as delivery systems to transport drugs for neurodegenerative diseases, which cannot cross the blood-brain barrier to enter the central nervous system. This manuscript is focused on pharmaceutical products either containing lactoferrin as the bioactive component or formulated with lactoferrin as the carrier considering its interaction with receptors expressed in tissues as targets of drugs delivered via parenteral or mucosal administration. We hope that this manuscript provides insights about the therapeutic possibilities of pharmaceutical Lf preparations with a sustainable approach that contributes to decreasing the resistance of antimicrobials and enhancing the bioavailability of first-line drugs for intestinal chronic inflammation and neurodegenerative diseases.
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Pharmaceuticals (Basel) Año: 2023 Tipo del documento: Article País de afiliación: México

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Pharmaceuticals (Basel) Año: 2023 Tipo del documento: Article País de afiliación: México